Johnson & Johnson sets up second offering period for Cougar
This article was originally published in Scrip
Johnson & Johnson has set up a second offering period for shares in Cougar Biotechnology, which will expire on July 9th – its initial tendering period ended on July 2nd with it receiving 84.4% of the shares of Cougar Biotechnology.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.